Publications by authors named "Uros Smrdel"

Claim this Profile
C
Cognitive functioning is prognostic in patients with IDH1-wild type and MGMT-unmethylated high-grade gliomas.
Uroš Smrdel, Andreja Cirila Škufca Smrdel, Anja Podlesek, Marija Skoblar Vidmar, Gregor Kos

Croat Med J· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cognitive functioning in a cohort of high-grade glioma patients.
Andreja Cirila Skufca Smrdel, Anja Podlesek, Marija Skoblar Vidmar, Jana Markovic, Jana Jereb, Uros Smrdel

Radiol Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Value of FET PET/CT in Recurrent Glioma with a Different IDH Mutation Status: The Relationship between Imaging and Molecular Biomarkers.
Marija Skoblar Vidmar, Andrej Doma, Uroš Smrdel, Katarina Zevnik, Andrej Studen

Int J Mol Sci· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glioblastoma in Patients over 70 Years of Age.
Uros Smrdel, Marija Skoblar Vidmar, Ales Smrdel

Radiol Oncol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term survival in glioblastoma: methyl guanine methyl transferase (MGMT) promoter methylation as independent favourable prognostic factor.
Uros Smrdel, Mara Popovic, Matjaz Zwitter, Emanuela Bostjancic, Andrej Zupan

Radiol Oncol· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glioblastoma patients in Slovenia from 1997 to 2008.
Uros Smrdel, Viljem Kovac, Mara Popovic, Matjaz Zwitter

Radiol Oncol· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II trial of low-dose gemcitabine in a prolonged infusion and cisplatin for malignant pleural mesothelioma.
Viljem Kovac, Matjaz Zwitter, Mirjana Rajer, Aleksander Marin, Andrej Debeljak, Uros Smrdel

Anticancer Drugs· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intermittent chemotherapy and erlotinib for nonsmokers or light smokers with advanced adenocarcinoma of the lung: a phase II clinical trial.
Matjaz Zwitter, Mirjana Rajer, Viljem Kovac, Izidor Kern, Martina Vrankar, Uros Smrdel

J Biomed Biotechnol· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Two schedules of chemotherapy for patients with non-small cell lung cancer in poor performance status: a phase II randomized trial.
Matjaz Zwitter, Viljem Kovac, Mirjana Rajer, Martina Vrankar, Uros Smrdel

Anticancer Drugs· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic markers in oligodendroglial tumours.
Tomaz Velnar, Uros Smrdel, Mara Popovic, Gorazd Bunc

Radiol Oncol· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gemcitabine in brief versus prolonged low-dose infusion, both combined with cisplatin, for advanced non-small cell lung cancer: a randomized phase II clinical trial.
Matjaz Zwitter, Viljem Kovac, Uros Smrdel, Martina Vrankar, Vesna Zadnik

J Thorac Oncol· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gemcitabine, cisplatin, and hyperfractionated accelerated radiotherapy for locally advanced non-small cell lung cancer.
Matjaz Zwitter, Viljem Kovac, Uros Smrdel, Primoz Strojan

J Thorac Oncol· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis